Log in

Galera Therapeutics Stock Forecast, Price & News

+0.39 (+3.29 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $12.24
50-Day Range
MA: $9.74
52-Week Range
Now: $12.24
Volume63,000 shs
Average Volume48,849 shs
Market Capitalization$304.56 million
P/E RatioN/A
Dividend YieldN/A
Galera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis. It is also involved in developing GC4711, which is in Phase I clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GRTX



Sales & Book Value

Annual SalesN/A
Book Value$2.81 per share


Net Income$-51,930,000.00


Market Cap$304.56 million
Next Earnings Date12/8/2020 (Estimated)
OptionableNot Optionable
+0.39 (+3.29 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Galera Therapeutics (NASDAQ:GRTX) Frequently Asked Questions

How has Galera Therapeutics' stock been impacted by Coronavirus?

Galera Therapeutics' stock was trading at $10.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GRTX shares have increased by 12.0% and is now trading at $12.24.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Galera Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Galera Therapeutics

When is Galera Therapeutics' next earnings date?

Galera Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, December 8th 2020.
View our earnings forecast for Galera Therapeutics

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics (NASDAQ:GRTX) posted its quarterly earnings data on Monday, August, 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.01.
View Galera Therapeutics' earnings history

What price target have analysts set for GRTX?

4 equities research analysts have issued 1-year target prices for Galera Therapeutics' stock. Their forecasts range from $8.00 to $30.00. On average, they expect Galera Therapeutics' share price to reach $18.25 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts' price targets for Galera Therapeutics

Who are some of Galera Therapeutics' key competitors?

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), CorMedix (CRMD), Ardelyx (ARDX), Chiasma (CHMA), NGM Biopharmaceuticals (NGM), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).

Who are Galera Therapeutics' key executives?

Galera Therapeutics' management team includes the following people:
  • Dr. J. Mel Sorensen, CEO, Pres & Director (Age 62)
  • Dr. Robert A. Beardsley, Co-Founder, COO & Sec. (Age 58)
  • Mr. Christopher Degnan, Chief Financial Officer (Age 40)
  • Mr. Joel F. Sussman, Chief Accounting Officer (Age 70)
  • Dr. Dennis P. Riley Ph.D., Chief Scientific Officer

When did Galera Therapeutics IPO?

(GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

What is Galera Therapeutics' stock symbol?

Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX."

Who are Galera Therapeutics' major shareholders?

Galera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Wealth Management Partners (0.25%). Company insiders that own Galera Therapeutics stock include Bioventures Ltd Novartis, Enterprise Associates 14 New, Holdings A/S Novo and Jon T Holmlund.
View institutional ownership trends for Galera Therapeutics

Which institutional investors are buying Galera Therapeutics stock?

GRTX stock was bought by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners. Company insiders that have bought Galera Therapeutics stock in the last two years include Enterprise Associates 14 New, and Holdings A/S Novo.
View insider buying and selling activity for Galera Therapeutics

How do I buy shares of Galera Therapeutics?

Shares of GRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galera Therapeutics' stock price today?

One share of GRTX stock can currently be purchased for approximately $12.24.

How big of a company is Galera Therapeutics?

Galera Therapeutics has a market capitalization of $304.56 million. The company earns $-51,930,000.00 in net income (profit) each year or ($16.31) on an earnings per share basis. Galera Therapeutics employs 26 workers across the globe.

What is Galera Therapeutics' official website?

The official website for Galera Therapeutics is www.galeratx.com.

How can I contact Galera Therapeutics?

Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The company can be reached via phone at 610-725-1500 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.